Very a bit provocative perhaps by telling you that I am a strong believer of the view that the immunoglobulin is perhaps the ultimate driver for CLL genesis and evolution. So we do have so much evidence. In fact, finding to this direction, not least the fact that you see patients with gross genomic aberrations that lead to perturbations in the control of cell cycle.
And yet, these patients respond to drugs like ibrutinib that block interactions with a micro-environment, which clearly points to the importance of microenvironmental triggers that are perceived amongst other things through the immunoglobulin...
Very a bit provocative perhaps by telling you that I am a strong believer of the view that the immunoglobulin is perhaps the ultimate driver for CLL genesis and evolution. So we do have so much evidence. In fact, finding to this direction, not least the fact that you see patients with gross genomic aberrations that lead to perturbations in the control of cell cycle.
And yet, these patients respond to drugs like ibrutinib that block interactions with a micro-environment, which clearly points to the importance of microenvironmental triggers that are perceived amongst other things through the immunoglobulin. So in this workshop, we will cover a bit of the biology, but particularly a lot of the various technical aspects pertaining to immunoglobulin gene analysis in a clinical setting, and also the clinical relevance of accurate immunogenetic analysis. So how to report correct results of the clinicians and what the clinicians should be doing once they get these results.